Kerberos Biopharma is an emerging Philadelphia based biotechnology company targeting metastatic cancer. There is considerable evidence for the involvement of chemokines in cancer, both in tumor progression and metastatic dissemination of the disease. Kerberos is the world-leader in the research and development of highly potent small molecule antagonists of CX3CR1 and has identified and profiled an IND candidate with back-ups targeting Inflammatory Breast Cancer (IBC) as its first indication.
Kerberos has raised approximately $3M in grant and research funding to date and is actively fundraising to advance its lead program into clinical development for IBC, an orphan drug indication with potential breakthrough regulatory designation.
Company Details
- Founded
- -
- Address
- 3001 Market Street,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.kerberospharma.com
- Keywords
- Biotechnology and Pharmaceuticals.
- HQ
- Philadelphia, Pennsylvania
- Competitors
Kerberos Biopharma Questions
Kerberos Biopharma's website is http://www.kerberospharma.com
Kerberos Biopharma's LinkedIn profile is https://www.linkedin.com/company/kerberos-biopharma
Kerberos Biopharma's industry is
Biotechnology Research
Kerberos Biopharma's categories are Biotechnology Research
Kerberos Biopharma's founding year is 2013
